Ultragenyx CFO sells 4,698 shares in open trade

Ultragenyx Pharmaceutical Inc. Chief Financial Officer Howard Horn reported an open-market sale of 4,698 shares of common stock at a price of $33.13 per share.

Accepted by SEC EDGAR 07/06/2026 - 03:37 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Ultragenyx Pharmaceutical Inc. Chief Financial Officer Howard Horn reported an open-market sale of 4,698 shares of common stock at a price of $33.13 per share. After this transaction, he directly owns 100,991 shares. His reported holdings include shares underlying previously granted RSUs that vest over time.

Insider Trade Summary 10b5-1

Net Seller: 4,698 shares

Net Sell 1 txn

Insider Horn Howard

Role Chief Financial Officer

Sold 4,698 shs ($156K)

Type	Security	Shares	Price	Value
Sale	Common Stock	4,698	$33.13	$156K

Holdings After Transaction: Common Stock — 100,991 shares (Direct)

Footnotes (1)

1. F1. Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.

Key Figures

Shares sold: 4,698 shares Sale price: $33.13 per share Shares owned after: 100,991 shares

3 metrics

Shares sold 4,698 shares Open-market sale of common stock

Sale price $33.13 per share Price for the 4,698 shares sold

Shares owned after 100,991 shares Direct ownership following the transaction

Key Terms

Common Stock, open-market sale, RSUs

3 terms

Common Stock financial

"security_title: "Common Stock" in the transaction record"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

open-market sale financial

"transaction_action: "open-market sale" describing the trade"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

RSUs financial

"shares of common stock underlying RSUs granted to the Reporting Person"

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Ultragenyx (RARE) disclose for CFO Howard Horn?

Ultragenyx reported that CFO Howard Horn sold 4,698 shares of common stock. The shares were sold in an open-market transaction at $33.13 per share, and he continues to hold 100,991 shares directly after the sale.

At what price did Ultragenyx (RARE) CFO Howard Horn sell his shares?

Howard Horn sold his Ultragenyx shares at $33.13 per share. The Form 4 shows a single open-market sale of 4,698 common shares at this price, providing transparency into the exact execution level for the transaction.

How many Ultragenyx (RARE) shares does CFO Howard Horn hold after the sale?

After the reported sale, Howard Horn holds 100,991 Ultragenyx shares. This figure reflects his direct ownership and includes previously reported shares underlying RSUs that are subject to vesting conditions described in the footnote.

Was the Ultragenyx (RARE) CFO trade a buy or a sell?

The Ultragenyx CFO transaction was a sale of shares. The Form 4 uses transaction code "S" and describes the action as an open-market sale, indicating that 4,698 common shares were sold rather than acquired.

Do Ultragenyx (RARE) CFO holdings include RSUs after this Form 4?

Yes, the CFO’s reported holdings include shares underlying RSUs. A footnote explains that the total common stock count incorporates previously reported RSU awards that are still subject to vesting conditions, which may affect when those shares fully vest.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Horn Howard

(Last) (First) (Middle)

C/O ULTRAGENYX PHARMACEUTICAL INC.

60 LEVERONI COURT

(Street)

NOVATO CALIFORNIA 94949

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Ultragenyx Pharmaceutical Inc. [ RARE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/01/2026		S		4,698	D	$33.13	100,991(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.

	/s/ Karah Parschauer, attorney-in-fact	07/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)